Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 148 of 5804
-
New hope for kids with tough leukemia: targeted drugs added to chemo
Disease control Recruiting nowThis is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma or mixed phenotype acute leukemia. Primary O…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New trial aims to stop deadly blood clots with quick catheter action
Disease control Recruiting nowProspective, multicenter, open label, randomized controlled clinical trial to compare the effects of an early catheter-directed treatment plus conventional care with conventional care in patients with high-risk pulmonary embolism
Phase: NA • Sponsor: Leipzig Heart Science gGmbH • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Fish oil in pregnancy may cut childhood asthma risk, major trial launches
Prevention Recruiting nowThe overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could…
Phase: PHASE3 • Sponsor: Professor Klaus Bønnelykke • Aim: Prevention
Last updated Jun 27, 2026 07:53 UTC
-
New hope for rare eye cancer: experimental combo aims to shrink tumors and extend life
Disease control Recruiting nowThe purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Phase: PHASE2, PHASE3 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for lung cancer: YL201 takes on relapsed SCLC in major trial
Disease control OngoingThis study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to cure chronic hepatitis b in landmark trial
Disease control OngoingThe study is to evaluate the efficacy and safety of AHB-137 in CHB participants. The total duration of the study, including screening phase, treatment phase and follow-up phase.
Phase: PHASE2 • Sponsor: Ausper Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New hope for Hard-to-Treat colorectal cancer: amivantamab combo enters phase 3
Disease control Recruiting nowThe purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic a…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Lung cancer trial tests whether chemo before surgery boosts survival
Disease control Recruiting nowThis phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual appro…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immune booster may strengthen stem cell transplant against hodgkin lymphoma
Disease control Recruiting nowThis is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autolo…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New vaccine aims to outsmart Drug-Resistant lung cancer
Disease control Recruiting nowMulticenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control …
Phase: PHASE3 • Sponsor: OSE Immunotherapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could a shot replace daily HIV pills for those with uncontrolled virus?
Disease control OngoingThis study will assess how effective, safe, and long-lasting a long-acting antiretroviral therapy (ART) using CAB LA + RPV LA is for people with HIV who still have detectable virus levels despite being on oral ART. The study will also consider feedback from patients on their expe…
Phase: PHASE3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Triple therapy takes on tough lung cancer
Disease control Recruiting nowBased on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could f…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for EGFR lung cancer: experimental drug SHR-A2009 takes on chemo in phase 3 trial
Disease control OngoingThis study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TK…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immunotherapy combo before surgery shows promise for tough mesothelioma
Disease control Recruiting nowThis phase II trial evaluates the safety and effectiveness of giving immunotherapy (nivolumab and ipilimumab) before surgery for controlling disease in patients with stage I-IIIa sarcomatoid mesothelioma. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab,…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug duo aims to outperform chemo in tough lung cancer
Disease control OngoingThis is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed dea…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Could a new pill tame Autism-Related irritability in kids?
Symptom relief Recruiting nowThis is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition…
Phase: PHASE3 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Engineered immune cells take on late-stage lymphoma in new trial
Disease control Recruiting nowSingle-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years. The total duration of the study is therefore of 7 years.
Phase: PHASE2 • Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a vaccine stop recurrent UTIs? new trial underway
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and includ…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:23 UTC
-
New stem cell transplant trial aims to treat sickle cell disease and other blood disorders
Disease control Recruiting nowA single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for AML patients? quizartinib trial targets Tough-to-Treat leukemia
Disease control OngoingThis study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC